Ziopharm Oncology (ZIOP)

Company Description

ZIOPHARM Oncology (ZIOP) is a second-generation gene therapy company focused on the development of new cancer treatments with a laser focus on the red-hot immune oncology (I/O) sector. ZIOP licensed its gene expression control technology from synthetic-biology innovator Intrexon for use in the development of DNA-based oncology treatments. Under an exclusive channel partner agreement, the two companies have collaborated to develop a tightly controlled system that injects a gene-expression package into tumors to express the anti-tumor cytokine interleukin-12 (IL-12), but only when patients take a pill that contains a ligand to activate the IL-12 gene. When the patient stops taking the pill, IL-12 expression stops, allowing for specific dosing for a set time. Expression is controlled by Intrexon’s proprietary biologic switch known as the RheoSwitch. The ability to administer or withdraw the pill to control gene expression is a key safety benefit.


1 First Avenue
Parris Building, #34
Navy Yard Plaza
Boston, MA 02129
United States

(617) 259-1970


Get BioInvest's perspective on Ziopharm's CEO

Latest Company News

ZIOPHARM Oncology Inc (ZIOP) Moves Lower on Volume Spike for March 21 Equities.com - Mar 21, 2017 ZIOPHARM Oncology Inc (ZIOP) traded on unusually high volume on Mar. 21, as the stock lost 5.93% to close at $5.87. On the day, ZIOPHARM Oncology Inc saw 2.04 million shares trade hands on 9,729 trades. Considering that the stock averages only a ... What Are Analysts Report About ZIOPHARM Oncology, Inc. (ZIOP) - News Oracle [...]
Tue, Mar 21, 2017 9:30:00 PM, Continue reading at the source
Griffin Commends ZIOPHARM Oncology Inc. (ZIOP) Following Suspension Of Breast ... Smarter Analyst - Feb 27, 2017 ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has indicating the firm will be shifting its R&D pipeline, centering its IL-12 gene therapy program on glioblastoma following the suspension of future development of its breast cancer therapy program. Sizling Stock Update: ZIOPHARM Oncology, Inc. (UTC:ZIOP) - HugoPress [...]
Mon, Feb 27, 2017 3:56:00 PM, Continue reading at the source
Company Update (NASDAQ:ZIOP): ZIOPHARM Oncology Inc. Announces 4Q:16 Financial ... Smarter Analyst - Feb 16, 2017 ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) announced financial results for the fourth quarter ended December 31, 2016, and provided an update on the Company's recent activities. Ziopharm 4Q Loss 11 Cents a Share (ZIOP) - Investopedia ZIOPHARM Reports Fourth-Quarter 2016 Financial Results and Provides Update on ... - GlobeNewswire (press release) [...]
Thu, Feb 16, 2017 9:34:00 PM, Continue reading at the source
Griffin Lifts Price Target on ZIOPHARM Oncology Inc. (ZIOP) Ahead of ... Smarter Analyst - Feb 9, 2017 Griffin analyst Keith Markey sees golden prospects ahead for ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), particularly taking into account the seven clinical trials the firm has forthcoming on the table for this year; trials which the analyst commends as ... ZIOPHARM Oncology, Inc. (UTC:ZIOP) added about 7.4 percent in value since last ... - The Independent Republic [...]
Thu, Feb 09, 2017 1:01:00 PM, Continue reading at the source
Company Update (NASDAQ:ZIOP): ZIOPHARM Oncology Inc. And Intrexon Corp To ... Smarter Analyst - Jan 10, 2017 ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) and Intrexon Corp (NYSE:XON) announced the signing of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of adoptive cell transfer ... [...]
Tue, Jan 10, 2017 2:36:00 PM, Continue reading at the source
The Reason Behind ZIOPHARM Oncology Inc.'s 11% Gain Motley Fool - Nov 10, 2016 Shares of ZIOPHARM Oncology (NASDAQ:ZIOP), a clinical-stage biopharmaceutical company focused on the development of various immunotherapeutic cancer treatments, surged as much as 11% during Thursday's trading session after the company ... Stock Update (NASDAQ:ZIOP): ZIOPHARM Oncology Inc. Reports Third Quarter 2016 ... - Smarter Analyst [...]
Thu, Nov 10, 2016 8:02:00 PM, Continue reading at the source
Better Buy: Ziopharm Oncology, Inc. vs. Juno Therapeutics Motley Fool - Nov 3, 2016 And although it hasn't been as closely associated with CAR-T as Juno Therapeutics, Ziopharm Oncology (NASDAQ:ZIOP) is part of a collection of entities (including Intrexon, Merck, and MD Anderson) developing a therapeutic pipeline in the same class, ... ZIOPHARM Announces Four Presentations at the 2016 ASH Annual Meeting - GlobeNewswire (press release) [...]
Thu, Nov 03, 2016 3:41:00 PM, Continue reading at the source
Better Buy: Ziopharm Oncology, Inc. vs. Intrexon Corporation Motley Fool - Oct 14, 2016 The close relationship between Ziopharm Oncology (NASDAQ:ZIOP) and Intrexon (NYSE:XON) hasn't gone unnoticed by investors -- in fact, it's impossible to overlook since the latter is likely responsible for a majority of the former's $660 million market cap. [...]
Fri, Oct 14, 2016 7:41:00 PM, Continue reading at the source
Better Buy: Ziopharm Oncology, Inc. vs. Alnylam Pharmaceuticals, Inc. Motley Fool - Sep 24, 2016 Clinical-stage biotechs Ziopharm Oncology (NASDAQ:ZIOP) and Alnylam Pharmaceuticals (NASDAQ:ALNY), for example, have both suffered in 2016. [...]
Sat, Sep 24, 2016 11:48:00 AM, Continue reading at the source
Better Buy: Ziopharm Oncology, Inc. vs. Celgene Motley Fool - Jun 18, 2016 One of the coolest kids on the T-cell block to receive a market beatdown was clinical-stage Ziopharm Oncology, Inc. (NASDAQ:ZIOP). [...]
Sat, Jun 18, 2016 6:05:00 PM, Continue reading at the source